Hirotsugu Ariizumi
Overview
Explore the profile of Hirotsugu Ariizumi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
255
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsurui T, Hamada K, Mura E, Suzuki R, Iriguchi N, Ishiguro T, et al.
Front Oncol
. 2025 Feb;
15:1499650.
PMID: 39980541
Introduction: In patients with cancer, sarcopenia is an indicator of poor prognosis and is associated with an increased risk of chemotherapy-related adverse events. Skeletal muscle interacts with the immune system,...
2.
Ishiguro T, Takeda K, Takayanagi D, Mura E, Suzuki R, Tsurui T, et al.
Cancer Genomics Proteomics
. 2024 Dec;
22(1):1-12.
PMID: 39730175
Background/aim: The Kaplan-Meier curves for patients treated with immune checkpoint inhibitors (ICIs) display a small group of potentially-cured patients with long-term survival, creating a 'kangaroo-tail' shape of the survival curve....
3.
Tsurui T, Ariizumi H, Kubota Y, Tsunoda T
Cureus
. 2024 Dec;
16(11):e74474.
PMID: 39726453
Immune checkpoint inhibitors (ICIs) have dramatically improved the prognosis of patients with cancers. However, ICIs can provoke systemic toxicities, which are known as immune-related adverse events (irAEs). Polymyalgia rheumatica (PMR)-like...
4.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, et al.
Front Oncol
. 2024 Oct;
14:1449941.
PMID: 39464714
Introduction: Immune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for esophageal cancer (EC). Although ICIs enable long-term survival in some patients, the efficacy of ICIs varies widely...
5.
Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, et al.
Sci Rep
. 2024 Oct;
14(1):23401.
PMID: 39379424
Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression....
6.
Hirasawa Y, Kubota Y, Mura E, Suzuki R, Tsurui T, Iriguchi N, et al.
Anticancer Res
. 2024 Jul;
44(8):3397-3407.
PMID: 39060084
Background/aim: Immune checkpoint inhibitors (ICIs) play an important role in the treatment of esophageal cancer (EC). However, few patients achieve long-term survival, and some patients develop serious immune-related adverse events...
7.
Murayama M, Hosonuma M, Kuramasu A, Kobayashi S, Sasaki A, Baba Y, et al.
Sci Rep
. 2024 May;
14(1):11325.
PMID: 38760458
The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In...
8.
Otsuka K, Isobe J, Asai Y, Nakano T, Hattori K, Ariyoshi T, et al.
Cancer Immunol Immunother
. 2024 Jan;
73(2):23.
PMID: 38280026
Background: Recently, intestinal bacteria have attracted attention as factors affecting the prognosis of patients with cancer. However, the intestinal microbiome is composed of several hundred types of bacteria, necessitating the...
9.
Hosonuma M, Hirasawa Y, Kuramasu A, Murayama M, Narikawa Y, Toyoda H, et al.
Cancer Sci
. 2024 Jan;
115(3):752-762.
PMID: 38254257
Immune checkpoint inhibitor discovery represents a turning point in cancer treatment. However, the response rates of solid tumors remain ~10%-30%; consequently, prognostic and immune-related adverse event (irAE) predictors are being...
10.
Goshima T, Ieguchi K, Onishi N, Shimizu T, Takayanagi D, Watanabe M, et al.
Anticancer Res
. 2023 Dec;
44(1):23-29.
PMID: 38159965
Background/aim: The response rate to immune checkpoint inhibitors (ICIs) is approximately 10%-30% and only in a few cancer types. In the present study, we determined whether non-classical monocytes (NCMs) could...